Skip to main content
Premium Trial:

Request an Annual Quote

Cyntellect to Collaborate with U of Florida on Cancer Stem Cells

NEW YORK (GenomeWeb News) – Cyntellect today said that it will collaborate with the University of Florida Interdisciplinary Center for Biotechnology Research on the purification and analysis of cancer stem cells.
The partners will use Cyntellect’s LEAP system to purify the stem cells “and their progeny without disturbing them from their growing environment,” said Cyntellect. The San Diego-based firm will receive certain payments and commercial rights to discoveries under the collaboration. Further details were not provided.
The collaboration will seek to “gain a better understanding of the molecular machinery, signaling pathways, and markers associated with rare cells, such as CSCs,” said Cyntellect CEO Fred Koller in a statement. “This information will be paramount to innovating novel drug development strategies and developing new cutting-edge diagnostics for crippling diseases, such as cancer.”
Cyntellect said that the alliance with the University of Florida is the second “major” LEAP collaboration this year. It expects further collaboration sin 2009 aimed at leveraging cell manipulation for discovering new drugs and cellular therapies and developing new cell-based diagnostics.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.